Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Amgen : Reports Outline Genetics Study Findings from Amgen (Graphtyper enables population-scale genotyping using pangenome graphs)

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 05:52pm CEST

By a News Reporter-Staff News Editor at Life Science Weekly -- Researchers detail new data in Life Science Research - Genetics. According to news reporting originating from Reykjavik, Iceland, by NewsRx correspondents, research stated, "A fundamental requirement for genetic studies is an accurate determination of sequence variation. While human genome sequence diversity is increasingly well characterized, there is a need for efficient ways to use this knowledge in sequence analysis."

Our news editors obtained a quote from the research from Amgen, "Here we present Graphtyper, a publicly available novel algorithm and software for discovering and genotyping sequence variants. Graphtyper realigns short-read sequence data to a pangenome, a variation-aware graph structure that encodes sequence variation within a population by representing possible haplotypes as graph paths. Our results show that Graphtyper is fast, highly scalable, and provides sensitive and accurate genotype calls. Graphtyper genotyped 89.4 million sequence variants in the whole genomes of 28,075 Icelanders using less than 100,000 CPU days, including detailed genotyping of six human leukocyte antigen (HLA) genes."

According to the news editors, the research concluded: "We show that Graphtyper is a valuable tool in characterizing sequence variation in both small and population-scale sequencing studies."

For more information on this research see: Graphtyper enables population-scale genotyping using pangenome graphs. Nature Genetics, 2017;():. (Nature Publishing Group - www.nature.com/; Nature Genetics - www.nature.com/ng/)

The news editors report that additional information may be obtained by contacting H.P. Eggertsson, deCODE Genetics, Amgen Inc, Reykjavik, Iceland. Additional authors for this research include H. Jonsson, S. Kristmundsdottir, E. Hjartarson, B. Kehr, G. Masson, F. Zink, K.E. Hjorleifsson, A. Jonasdottir, A. Jonasdottir, I. Jonsdottir, D.F. Gudbjartsson, P. Melsted, K. Stefansson and B.V Halldorsson (see also Life Science Research - Genetics).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1038/ng.3964. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Europe, Iceland, Genetics, Reykjavik, Life Science Research.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN
10:13p AMGEN : Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS® (Carfilzomib) Regimen ..
10/20 AMGEN : Announces Webcast of 2017 Third Quarter Financial Results
10/20 AMGEN : Engineered protein treatment found to reduce obesity in mice, rats and p..
10/20AMGEN, INC. : quaterly earnings release
10/20 AMGEN : and Boston Children's Hospital Enter a Collaboration to Find New Genes A..
10/19 AMGEN : Data on Lupus Reported by Researchers at Amgen (Safety, pharmacokinetics..
10/18 AMGEN : Kári Stefánsson Honored with Prestigious Award for Significant Contribut..
10/16 AMGEN : And Boston Children's Hospital Enter A Collaboration To Find New Genes A..
10/12 AMGEN : Wins Reprieve on Its 2nd-Best-Selling Drug
10/12 AMGEN : Reports on Biosimilars from Amgen Provide New Insights (A phase I, rando..
More news
News from SeekingAlpha
04:20p Amgen's Kyprolis dosed weekly shows treatment benefit over twice-weekly dosin..
12:35p BIOTECH FORUM DAILY DIGEST : Behind UniQure's Massive Rally
12:32p YOUR DAILY PHARMA SCOOP : Adamis Upside Potential, J&J's SIMPONI Label Expansion..
10:04a BIG BIOTECH IN THE CRISPR GAME : Novartis And Vertex Lead The Pack
10/22 More Wizardry For 2017 -- Magic Formula Large Cap Strategy Update, 2017 YTD
Financials ($)
Sales 2017 22 864 M
EBIT 2017 11 817 M
Net income 2017 8 137 M
Finance 2017 4 380 M
Yield 2017 2,46%
P/E ratio 2017 16,51
P/E ratio 2018 16,19
EV / Sales 2017 5,65x
EV / Sales 2018 5,51x
Capitalization 134 B
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 190 $
Spread / Average Target 4,1%
EPS Revisions
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN25.14%133 501
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116